The agency for enterprise competitiveness called ACCIÓ credited last June the technologies applied for health as a community RIS3CAT. Within this community, ACCIÓ has selected the project of research, development and innovation tomosíntesi 3D biopsy, in which Ventura Medical Technologies (BVentura) participates together with other institutions, such as IDNEO Technologies (FICOSA), the High Energy Physics Institute (IFAE), UDIAT Diagnostic Center – Parc Taulí Sabadell Foundation and the National Microelectronics Centre (CNM) – Centro Superior de Investigaciones Científicas (CSIC).
The RIS3CAT is a strategy for research and innovation promoted by the European Commission and approved by the Government of Catalonia which identifies seven sectorial leader areas where Catalonia has a competitive advantage, such as health industries and life sciences.
It is a commitment to R+D and innovation to encourage economic growth, generate new economic activity and new jobs opportunities.
RIS3CAT communities are groups of companies that drive plant performance R+D and innovation in the sectoral areas identified.
The R+D+I project
The aim of the 3D tomosíntesi biopsy project is to develop innovative products and technologies in the field of biopsy devices. This initiative aims to achieve a more optimal treatment planning and achieve a higher rate of post-treatment patient recovery.
Ventura Medical Technologies (BVentura) participates in this project in order to obtain a prototype of scientific instruments that allow test and validate a new technology that has a direct impact on the sustainability of the health system that can be applied in other sectors. Also, the initiative works to provide a software that may become warm hospitality automated processing of medical images.
The Agency for the Competitiveness of the Company (ACCIÓ) accredited the technologies applied to health as a RIS3CAT Community in 2016. 13 RIS3CAT Communities were promoted with a total budget of 53 million euros, some grants managed by ACCIÓ and part of all of which come from the European Regional Development Fund (ERDF). All of them mobilize an investment in research and innovation of over 140 million euros. One of them is part of the sectoral scope of the health and life sciences industries.
